Cargando…

Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel

PURPOSE: Chemotherapy of colon cancer needs improvement to mitigate the severe adverse effects (AEs) associated with the cytotoxic drugs. The aim of this study is to develop a novel targeted drug delivery system (TDDS) with practical application potential for colon cancer treatment. METHODS: The TDD...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhen, Li, Xundou, Duan, Jinhong, Yang, Xian-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494387/
https://www.ncbi.nlm.nih.gov/pubmed/32982230
http://dx.doi.org/10.2147/IJN.S267177
_version_ 1783582739870515200
author Yu, Zhen
Li, Xundou
Duan, Jinhong
Yang, Xian-Da
author_facet Yu, Zhen
Li, Xundou
Duan, Jinhong
Yang, Xian-Da
author_sort Yu, Zhen
collection PubMed
description PURPOSE: Chemotherapy of colon cancer needs improvement to mitigate the severe adverse effects (AEs) associated with the cytotoxic drugs. The aim of this study is to develop a novel targeted drug delivery system (TDDS) with practical application potential for colon cancer treatment. METHODS: The TDDS was built by loading docetaxel (DTX) in albumin nanoparticles (NPs) that were functionalized with nucleolin-targeted aptamers (AS1411). RESULTS: The TDDS (Apt-NPs-DTX) had an average size of 62 nm and was negatively charged with a zeta potential of −31.2 mV. DTX was released from the albumin NP with a typical sustained release profile. Aptamer-guided NPs were preferentially ingested by nucleolin-expressing CT26 colon cancer cells vs the control cells. In vitro cytotoxicity study showed that Apt-NPs-DTX significantly enhanced the killing of CT26 colon cancer cells. Importantly, compared with non-targeted drug delivery, Apt-NPs-DTX treatment significantly improved antitumor efficacy and prolonged the survival of CT26-bearing mice, without raising systemic toxicity. CONCLUSION: The results suggest that Apt-NPs-DTX has potential in the targeted treatment of colon cancer.
format Online
Article
Text
id pubmed-7494387
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74943872020-09-24 Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel Yu, Zhen Li, Xundou Duan, Jinhong Yang, Xian-Da Int J Nanomedicine Original Research PURPOSE: Chemotherapy of colon cancer needs improvement to mitigate the severe adverse effects (AEs) associated with the cytotoxic drugs. The aim of this study is to develop a novel targeted drug delivery system (TDDS) with practical application potential for colon cancer treatment. METHODS: The TDDS was built by loading docetaxel (DTX) in albumin nanoparticles (NPs) that were functionalized with nucleolin-targeted aptamers (AS1411). RESULTS: The TDDS (Apt-NPs-DTX) had an average size of 62 nm and was negatively charged with a zeta potential of −31.2 mV. DTX was released from the albumin NP with a typical sustained release profile. Aptamer-guided NPs were preferentially ingested by nucleolin-expressing CT26 colon cancer cells vs the control cells. In vitro cytotoxicity study showed that Apt-NPs-DTX significantly enhanced the killing of CT26 colon cancer cells. Importantly, compared with non-targeted drug delivery, Apt-NPs-DTX treatment significantly improved antitumor efficacy and prolonged the survival of CT26-bearing mice, without raising systemic toxicity. CONCLUSION: The results suggest that Apt-NPs-DTX has potential in the targeted treatment of colon cancer. Dove 2020-09-11 /pmc/articles/PMC7494387/ /pubmed/32982230 http://dx.doi.org/10.2147/IJN.S267177 Text en © 2020 Yu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yu, Zhen
Li, Xundou
Duan, Jinhong
Yang, Xian-Da
Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
title Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
title_full Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
title_fullStr Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
title_full_unstemmed Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
title_short Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
title_sort targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494387/
https://www.ncbi.nlm.nih.gov/pubmed/32982230
http://dx.doi.org/10.2147/IJN.S267177
work_keys_str_mv AT yuzhen targetedtreatmentofcoloncancerwithaptamerguidedalbuminnanoparticlesloadedwithdocetaxel
AT lixundou targetedtreatmentofcoloncancerwithaptamerguidedalbuminnanoparticlesloadedwithdocetaxel
AT duanjinhong targetedtreatmentofcoloncancerwithaptamerguidedalbuminnanoparticlesloadedwithdocetaxel
AT yangxianda targetedtreatmentofcoloncancerwithaptamerguidedalbuminnanoparticlesloadedwithdocetaxel